Bupa's purpose is helping people live longer, healthier, happier lives. With no shareholders, our customers are our focus. We reinvest profits into providing more and better healthcare for the benefit of current and future customers. Health insurance is at the core of our business globally. In some markets we also operate clinics, dental centres, hospitals, care homes and villages; giving us greater insight into how health systems work and enabling us to better meet the needs of our customers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

THERMO FISHER SCIENTIFIC ANNOUNCES ITS COMPLETE ACQUISITION OF MESA BIOTECH

Thermo Fisher Scientific | March 01, 2021

news image

Thermo Fisher Scientific Inc. (NYSE: TMO), the world chief in serving science, today reported it has finished its recently declared obtaining of Mesa Biotech, Inc., a secretly held purpose of-care sub-atomic analytic organization. Plateau Biotech has built up the Accula System, a moderate, simple to-utilize, purpose of-care PCR-based testing stage for irresistible infection conclusion. The stage empowers fast, exceptionally precise testing at doctor workplaces, drug stores and dif...

Read More

VIR BIOTECHNOLOGY AND WUXI BIOLOGICS ANNOUNCE COLLABORATION FOR GLOBAL DEVELOPMENT OF ANTIBODIES TO TREAT COVID-19

BioSpace | February 25, 2020

news image

Vir Biotechnology, Inc. and WuXi Biologics today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2. Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir’s proprietary antibodies. WuXi Biologics will conduct cell-line development, process and for...

Read More

Cell and Gene Therapy

ISOPLEXIS ACQUIRED A LARGE PORTFOLIO OF DNA AND RNA SEQUENCING TO ENABLE INTEGRATED SINGLE-CELL SEQUENCING AND PROTEOMIC SOLUTIONS

IsoPlexis | May 26, 2021

news image

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadma...

Read More

Diagnostics

ZIVO BIOSCIENCE ANNOUNCE JOINING RUSSELL MICROCAP® INDEX MEMBERSHIP

Zivo | June 28, 2022

news image

ZIVO Bioscience, Inc. is a U.S.-based R&D company dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains, announced joining the Russell Microcap® Index (^RUMIC) as a result of the Russell indexes annual reconstitution in 2022. Russell Microcap® Index membership that remains in place for a course of 12 months, means automatic inclusion in the appropriate value style and gr...

Read More
news image

Cell and Gene Therapy

THERMO FISHER SCIENTIFIC ANNOUNCES ITS COMPLETE ACQUISITION OF MESA BIOTECH

Thermo Fisher Scientific | March 01, 2021

Thermo Fisher Scientific Inc. (NYSE: TMO), the world chief in serving science, today reported it has finished its recently declared obtaining of Mesa Biotech, Inc., a secretly held purpose of-care sub-atomic analytic organization. Plateau Biotech has built up the Accula System, a moderate, simple to-utilize, purpose of-care PCR-based testing stage for irresistible infection conclusion. The stage empowers fast, exceptionally precise testing at doctor workplaces, drug stores and dif...

Read More
news image

VIR BIOTECHNOLOGY AND WUXI BIOLOGICS ANNOUNCE COLLABORATION FOR GLOBAL DEVELOPMENT OF ANTIBODIES TO TREAT COVID-19

BioSpace | February 25, 2020

Vir Biotechnology, Inc. and WuXi Biologics today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2. Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir’s proprietary antibodies. WuXi Biologics will conduct cell-line development, process and for...

Read More
news image

Cell and Gene Therapy

ISOPLEXIS ACQUIRED A LARGE PORTFOLIO OF DNA AND RNA SEQUENCING TO ENABLE INTEGRATED SINGLE-CELL SEQUENCING AND PROTEOMIC SOLUTIONS

IsoPlexis | May 26, 2021

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadma...

Read More
news image

Diagnostics

ZIVO BIOSCIENCE ANNOUNCE JOINING RUSSELL MICROCAP® INDEX MEMBERSHIP

Zivo | June 28, 2022

ZIVO Bioscience, Inc. is a U.S.-based R&D company dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains, announced joining the Russell Microcap® Index (^RUMIC) as a result of the Russell indexes annual reconstitution in 2022. Russell Microcap® Index membership that remains in place for a course of 12 months, means automatic inclusion in the appropriate value style and gr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us